ARFXF - ARFXF STOCK NEWS

ProMIS Neurosciences announced promising results for PMN310, its lead antibody therapeutic candidate for Alzheimer's disease. In the APP/L transgenic mouse model, PMN310 demonstrated significant cognitive benefits, preserving memory comparable to control mice. This aligns with current scientific understanding, emphasizing the role of toxic amyloid-beta oligomers in Alzheimer's pathology. The company plans to file for an IND by year-end for intravenous/infusion delivery and is also exploring a subcutaneous formulation.

ProMIS Neurosciences (OTCQB: ARFXF) has appointed Drs. Guy Rouleau and Alain Dagher to its scientific advisory board, enhancing its expertise in neurodegenerative diseases. Dr. Rouleau's background includes significant research on neurological and psychiatric disorders, while Dr. Dagher specializes in movement disorders, particularly Parkinson’s Disease. This strategic move aligns with ProMIS's focus on developing antibody therapeutics targeting toxic misfolded proteins linked to diseases like Alzheimer’s and ALS, reflecting its commitment to advancing treatment options.

ProMIS Neurosciences has appointed Dr. Cheryl Wellington to its Scientific Advisory Board, enhancing its focus on neurodegenerative diseases like Alzheimer's and traumatic brain injury. Dr. Wellington, a professor at UBC, brings expertise in blood-based biomarkers, which offer non-invasive advantages for clinical trials. The company emphasizes targeting misfolded proteins to advance its therapeutic approaches. Dr. Wellington expressed enthusiasm for ProMIS's mission to address the root causes of brain diseases, signaling potential advancements in treatment methodologies.

ProMIS Neurosciences (OTCQB: ARFXF) has launched a program aimed at developing monoclonal antibodies for treating schizophrenia and other chronic mental illnesses. The initiative stems from the association of protein misfolding with schizophrenia, particularly involving the DISC1 protein. Dr. Carsten Korth has joined the Scientific Advisory Board to provide expertise on this topic. ProMIS aims to leverage its proprietary computational methods to target misfolded proteins related to psychiatric disorders, similar to its efforts in neurodegenerative diseases.

ProMIS Neurosciences (OTCQB: ARFXF) will participate in the Biotech Showcase 2022 virtual panel on January 11, 2022, from 8 AM to 9 AM PST. CEO Eugene Williams, along with other industry leaders, will discuss advancements in antibody therapies targeting misfolded proteins in neurodegenerative diseases like Alzheimer's. Williams emphasizes the need for next-generation treatments that improve efficacy and tolerability compared to existing therapies like Aduhelm. Registration for the event and the agenda can be found on the Biotech Showcase website.

ProMIS Neurosciences, a biotechnology company focused on antibody therapeutics, announced its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10–13, 2022. The webcast of their presentation will be available on January 10 at 7:00 AM ET. CEO Eugene Williams will discuss the company's technology platform and their lead antibody candidate, PMN310, which targets toxic misfolded proteins related to neurodegenerative diseases like Alzheimer’s, ALS, and Parkinson’s. ProMIS is listed on the TSX as PMN and on the OTCQB as ARFXF.

ProMIS Neurosciences (OTCQB: ARFXF) reported strong 2021 progress and an optimistic outlook for 2022. They raised $27 million, enabling continued development of antibody therapeutics targeting neurodegenerative diseases like Alzheimer's and ALS. The company is advancing its lead program, PMN310, towards a first human clinical trial and has the support to potentially consolidate shares for a major stock exchange listing. ProMIS plans to expand its portfolio into new therapeutic targets, aiming to establish leadership in therapies for protein misfolding.

ProMIS Neurosciences announced that shareholders approved a share consolidation resolution at a special meeting on December 1, 2021. This allows the Board to consolidate shares at a ratio between thirty and sixty pre-consolidation shares to one post-consolidation share, effective before July 1, 2023. A total of 88.02% of votes favored the resolution. The Board aims to consolidate shares in conjunction with a potential US stock exchange listing, enhancing liquidity and capital access for development of therapies like PMN310. Approval from the Toronto Stock Exchange is pending, and no guarantees are made regarding the US listing.

ProMIS Neurosciences, focusing on antibody therapeutics for neurodegenerative diseases, announced its Q3 2021 financial results. The company reported revenues of $5,101, up from zero in 2020, while operating expenses increased to $2,045,560. Net loss decreased to $961,976 from $1,564,033 year-over-year. Significant operational progress includes advancements in the PMN310 program, expected to reach IND enabling activities in H2 2022. A focus on selective antibodies for Alzheimer's and ALS underscores the company's development strategy.